ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©Á¢ÒìÒ©ÑÎËáÌæÄÉÅÁŵƬ»ñÉÏÊÐÉêÇëÊÜÀí ÓÃÓÚÖÎÁÆÂýÐÔÉöÔಡѪ͸»¼Õ߸ßÁ×Ѫ֢
TenapanorƬÔÚÖйúµÄIIIÆÚÁÙ´²Ñо¿Ð§¹û֤ʵ¿ÉÏÔÖø½µµÍѪҺ͸Îö»¼ÕßÉý¸ßµÄѪÁ×ˮƽ¡£¡£¡£¡£¡£
£¨2023Äê7ÔÂ12ÈÕ£¬£¬£¬£¬£¬ÖйúÉϺ££©7ÔÂ12ÈÕ£¬£¬£¬£¬£¬ÉϺ£ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©£¨¼¯ÍÅ£©¹É·ÝÓÐÏÞ¹«Ë¾£¨¡°ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©¡±£¬£¬£¬£¬£¬¹ÉƱ´úÂ룺600196.SH£»£»£»£»£»02196.HK£©Ðû²¼£¬£¬£¬£¬£¬¿Ø¹É×Ó¹«Ë¾ÉϺ£ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©¹¤ÒµÉú³¤ÓÐÏÞ¹«Ë¾£¨¡°ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©¹¤Òµ¡±£©»ñÔÊÐíÁ¢ÒìÒ©TenapanorƬ£¨ÑÎËáÌæÄÉÅÁŵƬ£¬£¬£¬£¬£¬¡°¸ÃÐÂÒ©¡±£©ÓÃÓÚ¿ØÖÆÕýÔÚ½ÓÊÜѪҺ͸ÎöÖÎÁƵÄÂýÐÔÉöÔಡ£¡£¡£¡£¡£¨CKD£©³ÉÈË»¼ÕߵĸßÁ×Ѫ֢µÄÒ©Æ·×¢²áÉêÇëÓÚ¿ËÈÕ»ñ¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾Ö£¨¡°¹ú¼ÒÒ©¼à¾Ö¡±£©ÉóÆÀÊÜÀí¡£¡£¡£¡£¡£
TenapanorƬÊÇÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©´ÓArdelyxÔÊÐíÒýÈëµÄÒ»¿îFirst-in-class¿Ú·þ³¦µÀÄÆ/Çâ½»Á÷Ìå3£¨NHE3£©ÒÖÖÆ¼Á£¬£¬£¬£¬£¬2017Äê12Ô£¬£¬£¬£¬£¬ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©¹¤Òµ»ñµÃÁËTenapanorƬÔÚÖк£Äڵء¢Ïã¸Û¼°°ÄÃÅÌØÊâÐÐÕþÇøµÄ¶À¼ÒÁÙ´²¿ª·¢ºÍÉÌÒµ»¯µÈȨÁ¦¡£¡£¡£¡£¡£TenapanorƬΪ»¯Ñ§Ò©Æ·£¬£¬£¬£¬£¬¸ÃÐÂÒ©ÓÃÓÚ±ãÃØÐͳ¦Ò×¼¤×ÛºÏÖ¢ÖÎÁÆÒÑÓÚ2019Äê9Ô»ñÃÀ¹úFDA£¨¼´ÃÀ¹úʳÎïºÍÒ©Æ·¼àÊÓÖÎÀí¾Ö£©ÉÏÊÐÅú×¼£¬£¬£¬£¬£¬²¢ÒÑÓÚ2023Äê3ÔÂÔÚÖйúÏã¸ÛÌØÊâÐÐÕþÇøµÝ½»ÉÏÊÐÉêÇ룻£»£»£»£»×èÖ¹ÏÖÔÚ£¬£¬£¬£¬£¬¸Ã˳Ӧ֢ÓÚÖйú¾³ÄÚ£¨²»°üÀ¨¸Û°Ą̈µØÇø£©ÒÑÍê³ÉIÆÚÁÙ´²ÊÔÑé½×¶Î¡£¡£¡£¡£¡£TenapanorƬÓÃÓÚ³ÉÈËÂýÐÔÉöÔಡ£¡£¡£¡£¡£¨CKD£©Í¸Îö»¼ÕßµÄѪÇåÁ׿ØÖƵÄÉÏÊÐÉêÇëÕýÔÚ½ÓÊÜÃÀ¹úFDAµÄ×¢²áÉó²é¡£¡£¡£¡£¡£
TenapanorƬ¿ÉÒÔïÔ̳¦µÀÄÆÀë×ÓÎüÊÕ£¬£¬£¬£¬£¬ÔöÌí³¦Ç»ÄÚË®·Ö£¬£¬£¬£¬£¬Ôö½ø³¦µÀÈ䶯ºÍÕý³£ÅűãµÄƵÂÊ¡£¡£¡£¡£¡£¶àÏîÃÀ¹úºÍÈÕ±¾µÄ¢ò¡¢¢óÆÚÑо¿Åú×¢TenapanorƬ¿ÉÏÔÖø½µµÍѪҺ͸Îö»¼ÕßÉý¸ßµÄѪÁ×ˮƽ£¬£¬£¬£¬£¬ÔÚ³¤´ï52ÖܵÄÓÃÒ©ÊÔÑéÖÐÒ²ÏÔʾËüµÄÖÎÁÆ¿ÉÄÍÊÜÐÔ£¬£¬£¬£¬£¬ÔÚÖйúÖÕÄ©ÆÚÉöÔಡ£¡£¡£¡£¡£¨ESRD£©ÑªÍ¸°é¸ßÁ×Ѫ֢»¼ÕßÖпªÕ¹µÄTenapanorƬ¢óÆÚÑо¿Ð§¹ûÓëÒѽÒÏþÑо¿Ð§¹ûÒ»Ö£¬£¬£¬£¬£¬Î´·¢Ã÷еÄÇå¾²ÐÔÐźÅ1.2.3.¡£¡£¡£¡£¡£Ñо¿Ð§¹ûÖ§³ÖTenapanorƬÓÃÓÚÖйúESRDѪ͸°é¸ßÁ×Ѫ֢»¼ÕߵĽµÁ×ÖÎÁÆ¡£¡£¡£¡£¡£2023Äê6ÔÂ16ÈÕµÚ68½ìÈÕ±¾Í¸Îöҽѧ»áÄêÉÏ£¬£¬£¬£¬£¬ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©¿ÚÍ·»ã±¨ÁËTenapanorƬÖйúIIIÆÚÑо¿Ð§¹û¡£¡£¡£¡£¡£
***
²Î¿¼ÎÄÏ×£º
1.???Block GA, Rosenbaum DP, Yan A, Chertow GM. Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial. J Am Soc Nephrol 2019; 30: 641¨C52.
2.???Inaba M, Une Y, Ikejiri K, Kanda H, Fukagawa M, Akizawa T. Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial. Kidney Int Rep 2021; 7: 177¨C88.
3.???Block GA, Bleyer AJ, Silva AL, et al. Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM). Kidney360 2021; 2: 1600¨C10.
¹ØÓÚÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©
ÉϺ£ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©£¨¼¯ÍÅ£©¹É·ÝÓÐÏÞ¹«Ë¾£¨¡°ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©¡±£¬£¬£¬£¬£¬¹ÉƱ´úÂ룺600196.SH£¬£¬£¬£¬£¬02196.HK£©½¨ÉèÓÚ1994Ä꣬£¬£¬£¬£¬ÊÇÒ»¼ÒÖ²¸ùÖйú¡¢Á¢ÒìÇý¶¯µÄÈ«Çò»¯Ò½Ò©¿µ½¡¹¤Òµ¼¯ÍÅ£¬£¬£¬£¬£¬Ö±½ÓÔËÓªµÄÓªÒµ°üÀ¨ÖÆÒ©¡¢Ò½ÁÆÆ÷еÓëҽѧÕï¶Ï¡¢Ò½ÁÆ¿µ½¡Ð§ÀÍ£¬£¬£¬£¬£¬²¢Í¨¹ý²Î¹É¹úÒ©¿Ø¹ÉÁýÕÖµ½Ò½Ò©ÉÌÒµÁìÓò¡£¡£¡£¡£¡£
ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©ÒÔ»¼ÕßΪÖÐÐÄ¡¢ÁÙ´²ÐèÇóΪµ¼Ïò£¬£¬£¬£¬£¬Í¨¹ý×ÔÖ÷Ñз¢¡¢ÏàÖú¿ª·¢¡¢ÔÊÐíÒý½ø¡¢Éî¶È·õ»¯µÈ¶àÔª»¯¡¢¶àÌõÀíµÄÏàÖúģʽ£¬£¬£¬£¬£¬Ò»Á¬¸»ºñÁ¢Òì²úÆ·¹ÜÏߣ¬£¬£¬£¬£¬ÌáÉýFIC£¨First-in-class£¬£¬£¬£¬£¬¼´Í¬ÀàÊ×´´£©ÓëBIC£¨Best-in-class£¬£¬£¬£¬£¬¼´Í¬Àà×î¼Ñ£©ÐÂÒ©µÄÑо¿ÓëÁÙ´²¿ª·¢ÄÜÁ¦£¬£¬£¬£¬£¬¼ÓËÙÁ¢ÒìÊÖÒպͲúÆ·µÄÑз¢ºÍת»¯Â䵨¡£¡£¡£¡£¡£
ÔÚ¡°4IN¡±£¨Á¢ÒìInnovation¡¢¹ú¼Ê»¯Internationalization¡¢ÖÇÄÜ»¯Intelligentization¡¢ÕûºÏIntegration£©µÄÕ½ÂÔÖ¸µ¼Ï£¬£¬£¬£¬£¬ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©³Ð¼Ì¡°Á¢ÒìתÐÍ¡¢ÕûºÏÔËÓª¡¢ÎȽ¡ÔöÌí¡±µÄÉú³¤Ä£Ê½ÒÔ¼°Îª¹É¶«´´Á¢¼ÛÖµµÄÐÅÐÄ£¬£¬£¬£¬£¬Ò»Ö±ÔöÇ¿×ÔÖ÷Ñз¢ÓëÍⲿÏàÖú£¬£¬£¬£¬£¬¸»ºñ²úÆ·¹ÜÏߣ¬£¬£¬£¬£¬Ç¿»¯È«Çò»¯½á¹¹£¬£¬£¬£¬£¬ÌáÉýÔËӪЧÂÊ£¬£¬£¬£¬£¬Í¬Ê±£¬£¬£¬£¬£¬Æð¾¢ÍƽøÒ½ÁÆ¿µ½¡¹¤ÒµÏßÉÏÏßϽṹ£¬£¬£¬£¬£¬ÖÂÁ¦ÓÚ³ÉΪȫÇòÒ½ÁÆ¿µ½¡Êг¡µÄÒ»Á÷ÆóÒµ¡£¡£¡£¡£¡£
Ïàʶ¹«Ë¾¸ü¶à×ÊѶ¿ÉµÇ¼¹ÙÍø£ºwww.fosunpharma.com
ǰհÐÔÉùÃ÷£º
±¾ÐÂΟå°üÀ¨Ç°Õ°ÐÔÉùÃ÷¡£¡£¡£¡£¡£³ý±¾ÐÂΟåËùÔØµÄÀúÊ·ÊÂʵ³ÂÊöÍ⣬£¬£¬£¬£¬ËùÓаüÀ¨µ«²»ÏÞÓÚ±¾¹«Ë¾ÉÌÒµÕ½ÂÔµÄÌÖÂÛ£¬£¬£¬£¬£¬¹ØÓÚδÀ´ÔËÓª¡¢ÀûÈóÂÊ¡¢Ó¯ÀûÄÜÁ¦¡¢Á÷¶¯ÐÔºÍ×ÊÔ´×ÊÔ´¡¢±¾¹«Ë¾ÐÐҵδÀ´Éú³¤ºÍÖ÷ÒªÊг¡×ÜÌå¾¼ÃδÀ´Éú³¤µÄÔ¤ÆÚµÄÌÖÂÛ£¬£¬£¬£¬£¬ÒÔ¼°ÈκÎÔÚ´Ë֮ǰ¡¢Ö®ºó»ò°üÀ¨ÖîÈç¡°ÆÚÍû¡±¡¢¡°×·Ç󡱡¢¡°ÐÅÍС±¡¢¡°ÍýÏ롱¡¢¡°ÍýÏ롱¡¢¡°Ô¤¼Æ¡±¡¢¡°ÏîÄ¿¡±¡¢¡°Ô¤ÆÚ¡±¡¢¡°¿ÉÄÜ¡±¼°¡°½«Òª¡±µÈÓ빫˾»òÆäÖÎÀí²ãÓйصÄÀàËÆ´ÊÓï»ò³ÂÊö£¬£¬£¬£¬£¬¾ùÖ¼ÔÚÈ·¶¨Ç°Õ°ÐÔ³ÂÊö¡£¡£¡£¡£¡£ÕâЩ³ÂÊöÊÜijЩÒÑÖªºÍδ֪µÄΣº¦¡¢²»È·¶¨ÐԺͼÙÉèµÄÓ°Ïì¿ÉÄܵ¼Ö¹«Ë¾µÄÏÖʵЧ¹û¡¢Òµ¼¨»ò³É¼¨ÓëÕâЩǰհÐÔÉùÃ÷Ëù±í´ï»òÌåÏÖµÄÈκÎδÀ´Ð§¹û¡¢Òµ¼¨»ò³É¼¨±£´æÖØ´ó²î±ð¡£¡£¡£¡£¡£Òò´Ë£¬£¬£¬£¬£¬Äú²»Ó¦Ì«¹ýÒÀÀµÈκÎǰհÐÔµÄ×ÊÁÏ¡£¡£¡£¡£¡£Æ¾Ö¤ÊÊÓõÄÖ´·¨¡¢¹æÔòºÍÌõÀýµÄÒªÇ󣬣¬£¬£¬£¬ÎÞÂÛÊÇÓÉÓÚеÄÐÅÏ¢¡¢Î´À´ÊÂÎñ»òÉú³¤»òÆäËûÔµ¹ÊÔÓÉ£¬£¬£¬£¬£¬±¾¹«Ë¾Ã»ÓÐÒ²²»¼ç¸ºÈκθüлòÒÔÆäËû·½·¨Ð޸ı¾ÐÂΟåÖеÄǰհÐÔÉùÃ÷µÄÒåÎñ¡£¡£¡£¡£¡£ÔÚ±¾ÐÂΟåÖУ¬£¬£¬£¬£¬Óйع«Ë¾ÒâÏòµÄÉùÃ÷»ò²Î¿¼ÎÄÏ××Ô±¾ÐÂΟåÐû²¼Ö®ÈÕÆðÉúЧ¡£¡£¡£¡£¡£ÈκδËÀàÒâͼ¶¼¿ÉÄÜËæ×ÅδÀ´µÄÉú³¤¶ø¸Ä±ä¡£¡£¡£¡£¡£±¾ÐÂΟåËùÔØµÄËùÓÐǰհÐÔÉùÃ÷¾ù²ÎÕÕÉÏÊöÉêâÁÐÔÉùÃ÷¼ÓÒÔÏÞÖÆ¡£¡£¡£¡£¡£




